SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)
Express News | Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics
CCORF Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $56
CCORF analyst Edward Nash maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $56.According to TipRanks data, the analyst has a success rate of 40.9% and a tot
Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46
Morgan Stanley analyst Michael Ulz maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 40.8%
Akero Therapeutics Initiated at Outperform by Wolfe Research
Akero Therapeutics Initiated at Outperform by Wolfe Research
Express News | Wolfe Research Initiates Coverage On Akero Therapeutics With Outperform Rating
Wolfe Research Starts Akero at Outperform, Cites MASH Drug Prospects
Wolfe Starts Madrigal at Outperform, Cites Rezdiffra Launch
Wolfe Research Initiates Coverage on Akero Therapeutics With Outperform Rating, $40 Price Target
Akero Therapeutics (AKRO) has an average rating of outperform and price targets ranging from $30 to $56, according to analysts polled by Capital IQ.
Akero Therapeutics Begins Phase 3 Study on Efruxifermin for Liver Disease Treatment
Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced
Express News | Akero Therapeutics Announces Initiation of Phase 3 Synchrony Outcomes Trial of Efruxifermin in Patients With Compensated Cirrhosis (F4) Due to Mash
H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Ed Arce maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 40.0% and
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients With Compensated Cirrhosis (F4) Due to MASH
PDF Version SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients
Wolfe Research Initiates Akero Therapeutics(AKRO.US) With Buy Rating, Announces Target Price $40
Wolfe Research analyst Andy Chen initiates coverage on $Akero Therapeutics(AKRO.US)$ with a buy rating, and sets the target price at $40.According to TipRanks data, the analyst has a success rate of 5
Reported Saturday, Akero Therapeutics Presented Data Highlighting The Efficacy And Safety Of EFX In Patients With MASH At EASL Congress
A late-breaking oral presentation will feature 96-week data from HARMONY, a Phase 2b study evaluating the efficacy and safety of EFX in patients with metabolic dysfunction-associated steatohepatitis (
Akero Therapeutics(AKRO.US) Officer Sells US$96,440 in Common Stock
$Akero Therapeutics(AKRO.US)$ Officer Young Jonathan sold 5,000 shares of common stock on Jun 3, 2024 at an average price of $19.288 for a total value of $96,440.Source: Announcement What is statement
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower.At the EASL International Liver Congress 2024, Eli Lilly And Co (NYSE
Eli Lilly and Co (LLY.US) is too strong, NASH concept stocks suffer a painful blow.
According to the Zhitong Finance app, the stock prices of drug developers for non-alcoholic steatohepatitis (NASH), a type of liver disease, fell on Wednesday. The reason is that earlier detailed data from Eli Lilly and Co's (LLY.US) weight loss drug, Tirzepatide, showed its potential in treating NASH. The data shows that Madrigal Pharmaceuticals (MDGL.US) fell more than 13%. It is understood that earlier this year, the company received FDA approval for its main asset, Rezafungin, used for NASH (also known as metabolic dysfunction-associated fatty liver disease, MASH).
Eli Lilly Details NASH Effects of Weight Loss Drug
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
PDF Version SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients w
No Data